'); } else { var query = elem.find('.keywords').html(); $.ajax({ context: elem, url: 'https://wn.com/api/upge/cheetah-search-adv/video', cache: true, data: { 'query': query }, dataType: 'jsonp', success: function(text) { if (text.length > 0) { video_id = text[0].id; elem.find('.player').html(''); } } }); } } var stopAllYouTubeVideos = function() { var iframes = document.querySelectorAll('iframe'); Array.prototype.forEach.call(iframes, function(iframe) { iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*'); }); } jQuery(function() { jQuery(".playVideo").live("click", function() { if(!$(this).hasClass("played")){ stopAllYouTubeVideos(); var elem = $(this); setTimeout(function(){ mouseOverMe(elem); }, 1000); } }); jQuery(".description_box .expandContent").live("click", function() { elem = $(this).parent().parent().parent().find('.descContent'); if(elem.height() > 51) { elem.css('height', '44px'); $(this).html('Show More '); }else{ elem.css('height', 'auto'); $(this).html('Hide '); } }); jQuery('.interview-play-off').click(function() { $(".interview-play-off").hide(); $(".interview-play").show(); $(".videoplayer-control-pause").click(); }); jQuery(".video-desc .show_author_videos").live("click", function() { query = $(this).attr('title'); container = $(this).parent().parent().parent().find('.video-author-thumbs'); $(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px'); jQuery.ajax({ url: '/api/upge/cheetah-photo-search/videoresults', data: {'query': query}, success: function(text) { if(!text) { text = i18n("No results"); } container.html(jQuery(text)); } }); }); }); // -->

Latest News for: biib

Edit

Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales

The Call 06 Feb 2026
BIIB) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion ... Biogen (BIIB) Q4 CY2025 Highlights. ... BIIB) develops and markets ...
Edit

Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse

The Call 06 Feb 2026
BIIB) stands at a critical crossroads in its nearly 50-year history ... The stock performance of Biogen (BIIB) reflects a company in the throes of a painful but necessary restructuring ... BIIB has surged ...
Edit

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

The Call 06 Feb 2026
BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner, growth-oriented neurology powerhouse.
Edit

Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings

The Call 05 Feb 2026
Biotech company Biogen (NASDAQ. BIIB) will be reporting results this Friday before market open. Here’s what investors should know ... Is Biogen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members ... P.S ... More News.
  • 1
×